Literature DB >> 2140495

Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia.

R T Davey1, H Masur.   

Abstract

In summary, recent advances in our ability to diagnose, treat, and prevent recurrences of pneumocystis pneumonia have significantly improved the clinical management of this infection, especially in HIV-1-infected individuals. As current investigations allow our therapeutic armamentarium in this disease to be strengthened even further, it is likely that pneumocystis pneumonia will pose a diminishing threat to those patients currently most susceptible to this infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140495      PMCID: PMC171632          DOI: 10.1128/AAC.34.4.499

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome.

Authors:  D E Stover; D A White; P A Romano; R A Gellene; W A Robeson
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

2.  Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  A E Pitchenik; P Ganjei; A Torres; D A Evans; E Rubin; H Baier
Journal:  Am Rev Respir Dis       Date:  1986-02

3.  Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.

Authors:  W T Hughes; S Feldman; S C Chaudhary; M J Ossi; F Cox; S K Sanyal
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

4.  Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome.

Authors:  C Broaddus; M D Dake; M S Stulbarg; W Blumenfeld; W K Hadley; J A Golden; P C Hopewell
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

5.  The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage.

Authors:  F P Ognibene; J Shelhamer; V Gill; A M Macher; D Loew; M M Parker; E Gelmann; A S Fauci; J E Parrillo; H Masur
Journal:  Am Rev Respir Dis       Date:  1984-06

6.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

7.  Utility of gallium67 scintigraphy and bronchial washings in the diagnosis and treatment of Pneumocystis carinii pneumonia in patients with the acquired immune deficiency syndrome.

Authors:  C U Tuazon; M D Delaney; G L Simon; P Witorsch; V M Varma
Journal:  Am Rev Respir Dis       Date:  1985-11

8.  Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.

Authors:  J A Golden; A Sjoerdsma; D V Santi
Journal:  West J Med       Date:  1984-11

9.  Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome.

Authors:  C M Stahl-Bayliss; C M Kalman; O L Laskin
Journal:  Clin Pharmacol Ther       Date:  1986-03       Impact factor: 6.875

10.  Rapid noninvasive diagnosis of Pneumocystis carinii from induced liquefied sputum.

Authors:  M K Zaman; O J Wooten; B Suprahmanya; W Ankobiah; P J Finch; S L Kamholz
Journal:  Ann Intern Med       Date:  1988-07-01       Impact factor: 25.391

View more
  19 in total

1.  Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Authors:  M J Gill; R Read
Journal:  Can J Infect Dis       Date:  1991

2.  Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia.

Authors:  B Ruf; I Rohde; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

3.  Pneumocystis carinii attachment increases expression of fibronectin-binding integrins on cultured lung cells.

Authors:  S T Pottratz; A L Weir; P E Wisniowski
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

Review 4.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

5.  Susceptibility of Pneumocystis carinii to artemisinin in vitro.

Authors:  S Merali; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

6.  Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii.

Authors:  M F Ypma-Wong; W A Fonzi; P S Sypherd
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

7.  Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.

Authors:  A Rosowsky; J B Hynes; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects.

Authors:  R C Stevens; S C Laizure; C L Williams; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.

Authors:  D S Stein; R C Stevens; D Terry; S C Laizure; S Palte; D J Lancaster; J J Weems; C L Williams
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy.

Authors:  J Blaser; B Joos; M Opravil; R Lüthy
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.